Trinity Biotech PLC (TRIB)
1.30
0.00 (0.00%)
USD |
NASDAQ |
Nov 21, 16:00
1.30
0.00 (0.00%)
After-Hours: 06:55
Trinity Biotech Revenue (Quarterly): 15.15M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
September 30, 2024 | 15.15M |
June 30, 2024 | 15.84M |
March 31, 2024 | 14.70M |
December 31, 2023 | 13.43M |
September 30, 2023 | 14.68M |
June 30, 2023 | 13.90M |
March 31, 2023 | 14.83M |
December 31, 2022 | 15.73M |
September 30, 2022 | 15.70M |
June 30, 2022 | 15.42M |
March 31, 2022 | 15.68M |
December 31, 2021 | 7.708M |
September 30, 2021 | 22.00M |
June 30, 2021 | 25.84M |
March 31, 2021 | 25.59M |
December 31, 2020 | 32.76M |
September 30, 2020 | 32.01M |
June 30, 2020 | 16.02M |
March 31, 2020 | 21.18M |
December 31, 2019 | 21.32M |
September 30, 2019 | 24.59M |
June 30, 2019 | 22.50M |
March 31, 2019 | 22.03M |
December 31, 2018 | 24.52M |
September 30, 2018 | 23.71M |
Date | Value |
---|---|
June 30, 2018 | 25.00M |
March 31, 2018 | 23.80M |
December 31, 2017 | 24.55M |
September 30, 2017 | 25.60M |
June 30, 2017 | 25.45M |
March 31, 2017 | 23.54M |
December 31, 2016 | 23.68M |
September 30, 2016 | 26.13M |
June 30, 2016 | 26.29M |
March 31, 2016 | 23.52M |
December 31, 2015 | 24.94M |
September 30, 2015 | 25.76M |
June 30, 2015 | 24.26M |
March 31, 2015 | 25.24M |
December 31, 2014 | 26.68M |
September 30, 2014 | 27.16M |
June 30, 2014 | 26.00M |
March 31, 2014 | 25.02M |
December 31, 2013 | 25.46M |
September 30, 2013 | 24.12M |
June 30, 2013 | 21.31M |
March 31, 2013 | 20.33M |
December 31, 2012 | 20.82M |
September 30, 2012 | 20.85M |
June 30, 2012 | 20.81M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
7.708M
Minimum
Dec 2021
32.76M
Maximum
Dec 2020
18.47M
Average
15.72M
Median
Revenue (Quarterly) Benchmarks
Amarin Corp PLC | 42.30M |
DBV Technologies SA | -- |
Ascendis Pharma AS | 63.61M |
Cellectis SA | 16.20M |
Adaptimmune Therapeutics PLC | 40.90M |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | -4.759M |
Total Expenses (Quarterly) | 17.37M |
EPS Diluted (Quarterly) | -0.46 |
Enterprise Value | 91.30M |
Gross Profit Margin (Quarterly) | 35.03% |
Profit Margin (Quarterly) | -31.41% |
Earnings Yield | -175.4% |
Normalized Earnings Yield | -165.32 |